跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
6-AN
首页
药物
6-AN
6-AN
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP 3421492 A1
申请人: JANSSEN BIOTECH INC
优先权: 2005
CN
EP
US
13 件公开
METHODS FOR TREATING INTERLEUKIN-6 RELATED DISEASES
EP 3167901 A1
申请人: CHUGAI PHARMACEUTICAL CO LTD
优先权: 2003
CN
EP
US
12 件公开
Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
US 9724410 B2
申请人: SMITH JEFFREY T L
优先权: 2010
US
7 件公开
METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE
EP 4281448 A1
申请人: BASF SE
优先权: 2021
CN
EP
US
WO
6 件公开
WO 2025252510 A1
申请人: BASF SE
优先权: 2024
WO
WO 2026008424 A1
申请人: BASF SE
优先权: 2024
WO
Method for preparing an enantiomerically enriched form of 3-(2-chlorothiazol-5-yl)-8-methyl-7-oxo-6-phenyl-2,3-dihydrothiazolo[3,2-ajpyrimidin-4-ium-5-olate
US 12559507 B2
申请人: BASF SE
优先权: 2021
CN
EP
US
WO
6 件公开
METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE
EP 4032894 A1
申请人: BASF SE
优先权: 2021
CN
EP
US
WO
6 件公开
Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
US 7320792 B2
申请人: CHUGAI PHARMACEUTICAL CO LTD
优先权: 2000
US
6 件公开
AN ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION COMPRISINGA,A,A-TRIFLUOROTHYMIDINE AND 5-CHLORO-6-(2-IMINOPYRROLIDINE-1-YL)METHYL-2,4 (1H,3H)-PYRIMIDINE DIONE HYDROCHLORIDE
EP 2815753 B2
申请人: TAIHO PHARMACEUTICAL CO LTD
优先权: 2012
CN
EP
US
WO
5 件公开
Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody
US 10961314 B2
申请人: FRESENIUS KABI DEUTSCHLAND GMBH
优先权: 2016
CN
EP
US
WO
5 件公开
TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT
EP 4013419 A1
申请人: HOFFMANN LA ROCHE
优先权: 2019
CN
EP
US
5 件公开
第 1 / 10 页
上一页
下一页
药物
反馈